Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Downgraded to Sell at BidaskClub

BidaskClub downgraded shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) from a hold rating to a sell rating in a report released on Tuesday, August 1st.

Other research analysts have also issued reports about the company. Royal Bank Of Canada reissued an outperform rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Jefferies Group LLC reissued a buy rating and set a $148.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, June 30th. Citigroup Inc. raised their price target on Zimmer Biomet Holdings from $108.00 to $130.00 and gave the company a neutral rating in a report on Friday, June 9th. Wells Fargo & Company reissued a market weight rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Finally, Piper Jaffray Companies reissued a buy rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings has a consensus rating of Hold and an average target price of $136.90.

Shares of Zimmer Biomet Holdings (NYSE:ZBH) traded up 1.43% during trading on Tuesday, reaching $111.70. 1,497,171 shares of the company’s stock traded hands. The company has a market capitalization of $22.59 billion, a price-to-earnings ratio of 31.81 and a beta of 1.20. The company has a 50 day moving average of $124.93 and a 200-day moving average of $121.26. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. Zimmer Biomet Holdings’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period last year, the business posted $2.02 earnings per share. Equities analysts predict that Zimmer Biomet Holdings will post $8.24 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://stocknewstimes.com/2017/08/12/zimmer-biomet-holdings-inc-nysezbh-lowered-to-sell-at-bidaskclub-updated.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. Zimmer Biomet Holdings’s payout ratio is presently 27.59%.

In other Zimmer Biomet Holdings news, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Parkside Financial Bank & Trust raised its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in shares of Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 167 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares in the last quarter. IHT Wealth Management LLC raised its stake in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares in the last quarter. Finally, Sandy Spring Bank raised its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares in the last quarter. Institutional investors and hedge funds own 83.62% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply